scholarly journals Point of care testing: lateral flow technology and beyond

2006 ◽  
Vol 27 (2) ◽  
pp. 70 ◽  
Author(s):  
Stuart Hazell ◽  
Hugh Swingler
Keyword(s):  
Point Of Care ◽  
Medical Science ◽  
Laboratory Medicine ◽  
Lateral Flow ◽  
Economic Pressure ◽  
Point Of Care Testing ◽  
The Real ◽  
Real Cost

For the last 50 years the pathology industry has been centralised and built around a strong skills base in laboratory medicine. Over recent decades, that skills base has been diluted as advances in technology have seen automation takeover many laboratory-based functions. These changes have, perversely, been driven by advances in medical science. With advances in medicine has come the demand for more intervention (testing) and the concomitant economic pressure to reduce the real cost of pathology testing as access is expanded.

A Self-Contained Chemiluminescent Lateral Flow Assay for Point-of-Care Testing

2018 ◽  
Vol 90 (15) ◽  
pp. 9132-9137 ◽  
Author(s):  
Jinqi Deng ◽  
Mingzhu Yang ◽  
Jing Wu ◽  
Wei Zhang ◽  
Xingyu Jiang
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Point Of Care Testing

scholarly journals Switching from Multiplex to Multimodal Colorimetric Lateral Flow Immunosensor

Sensors ◽  
2020 ◽  
Vol 20 (22) ◽  
pp. 6609
Author(s):  
Simone Cavalera ◽  
Fabio Di Nardo ◽  
Luca Forte ◽  
Francesca Marinoni ◽  
Matteo Chiarello ◽  
...  
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Proof Of Concept ◽  
Point Of Care Testing ◽  
Human Immunoglobulins ◽  
Immunodeficiency Virus ◽  
Specific Antigens ◽  
Increasing Demand ◽  
Gold Nanomaterials ◽  
Two Parameter

Multiplex lateral flow immunoassay (LFIA) is largely used for point-of-care testing to detect different pathogens or biomarkers in a single device. The increasing demand for multitargeting diagnostics requires multi-informative single tests. In this study, we demonstrated three strategies to upgrade standard multiplex LFIA to multimodal capacity. As a proof-of-concept, we applied the strategies to the differential diagnosis of Human Immunodeficiency Virus (HIV) infection, a widespread pathogen, for which conventional multiplex LFIA testing is well-established. In the new two-parameter LFIA (x2LFIA), we exploited color encoding, in which the binding of multiple targets occurs in one reactive band and the color of the probe reveals which one is present in the sample. By combining the sequential alignment of several reactive zones along the membrane of the LFIA strip and gold nanoparticles and gold nanostars for the differential visualization, in this demonstration, the x2LFIA can furnish information on HIV serotype and stage of infection in a single device. Three immunosensors were designed. The use of bioreagents as the capturing ligand anchored onto the membrane or as the detection ligand labelled with gold nanomaterials affected the performance of the x2LFIA. Higher detectability was achieved by the format involving the HIV-specific antigens as capturing agent and labelled secondary bioligands (anti-human immunoglobulins M and protein G) as the probes.

Point-of-Care Testing, a Critical Component of Laboratory Medicine

2009 ◽  
Vol 42 (3) ◽  
pp. 135 ◽  
Author(s):  
Catherine A. Hammett-Stabler ◽  
James H. Nichols
Keyword(s):  
Point Of Care ◽  
Laboratory Medicine ◽  
Critical Component ◽  
Point Of Care Testing
Sign in / Sign up

Export Citation Format

Share Document